Article thumbnail

Do neurologists in Germany adhere to the national Parkinson’s disease guideline?

By Sabrina Schröder, Daniel Kuessner, Guy Arnold, York Zöllner, Eddie Jones and Marion Schaefer


Implementation of guidelines can improve clinical practice. The aim in this study was to investigate whether neurologists in Germany adhered to the national Parkinson’s disease guideline. Data were obtained from a cross-sectional survey of 60 neurologists. Analyses were performed on 320 patients with idiopathic Parkinson’s disease with either low grades of functional impairment (Hoehn and Yahr stage I) or higher grades of functional impairment (stage II–V) but without motor complications. The sample was divided into four groups depending on age and grade of functional impairment. For each group, a biometric parameter on the use of dopamine agonists and L-dopa was defined based on the guideline. In patients aged <70 years, the recommendation to use dopamine agonists without L-dopa (parameter 1) was observed in 53% of patients with lower grades of functional impairment, whilst recommended use of dopamine agonists in more functionally impaired patients (parameter 2) was followed to a greater extent (84%). In patients aged ≥70 years, recommendations to use L-dopa without dopamine agonists were adhered to in only 50% of less functionally impaired (parameter 3) and 52% of more functionally impaired (parameter 4) patients. In conclusion, our results indicated there was moderate but not full adherence to the guideline

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). A reassessment of risks and benefits of dopamine agonists in Parkinson‘s disease. Lancet Neurol.
  2. (2006). A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging.
  3. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.
  4. (1999). Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing.
  5. (2001). An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Mov Disord.
  6. Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson’s disease. A National Survey of German neurologists in private practice.
  7. (2009). Awareness and knowledge of the clinical practice guideline on Parkinson’s disease among German neurologists. Eur Neurol.
  8. Drug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. pharmacoepidemiol Drug Saf.
  9. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations.
  10. (2000). Evaluation of a measurement strategy for Parkinson’s disease: assessing patient healthrelated quality of life. Qual Life Res.
  11. Health-related quality-of-life and healthcare utilisation in patients with Parkinson’s disease: impact of motor fluctuations and dyskinesias.
  12. (2003). Jahrgang
  13. (2008). Klinische “Leitlinien“ der deutschen Gesellschaft für Neurologie. Leitlinie für Diagnostik und Therapie in der Neurologie.
  14. Parkinson’s Disease Consensus Working Group (PDCWG). Guidelines for the management of Parkinson’s disease. Hosp Med.
  15. (2003). Practice guidelines for Parkinson’s disease. parkinsonism Rel Disord.
  16. Progression of motor impairment and disability in Parkinson disease: a populationbased study.
  17. Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand. Curr Med Res Opin.
  18. Success and problems of long-term levodopa therapy in Parkinson’s disease.
  19. (2007). The current treatment of Parkinson’s disease. Dtsch Arztebl.
  20. The economic impact of Parkinson’s disease. An estimation based on a 3-month prospective analysis.
  21. (2003). The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption – a nation-wide perspective in Sweden. parkinsonism Relat Disord.
  22. Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966–1998.
  23. (2004). Treatment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinic. CNS Drugs.
  24. Treatment interventions for Parkinson’s disease: an evidence based assessment.
  25. Why don’t physicians follow clinical practice guidelines? A framework for improvement.